Is The Opioid REMS Too Big To Study?
Executive Summary
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
You may also be interested in...
Unasked Questions: The Odd Dynamics Of FDA Commissioner Hearings
Is there anything less satisfying than a confirmation hearing for US FDA commissioner? Robert Califf performed very well during his testimony to return to the post, but no one who follows FDA closely likely learned much they did not already know.
Unasked Questions: The Odd Dynamics Of FDA Commissioner Hearings
Is there anything less satisfying than a confirmation hearing for US FDA commissioner? Robert Califf performed very well during his testimony to return to the post, but no one who follows FDA closely likely learned much they did not already know.
FDA Expanding Opioid REMS To Immediate Release Formulations
Commissioner Gottlieb tells opioid scientific workshop that updated REMS will also require training to be available to nurses and pharmacists; agency beginning new study on prescriber perceptions.